Cargando…

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2(nd) Generation Chimeric Antigen Receptor-Modified T Cells

While chimeric antigen receptor-modified T (CAR-T) cells have shown great success for the treatment of B cell leukemia, their efficacy appears to be compromised in B cell derived lymphoma and solid tumors. Optimization of the CAR design to improve persistence and cytotoxicity is a focus of the curre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Qiang, Han, Ping, Qi, Xinyue, Li, Fanlin, Li, Min, Fan, Lilv, Zhang, Huihui, Zhang, Xiaoqing, Yang, Xuanming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691374/ https://www.ncbi.nlm.nih.gov/pubmed/33281809 http://dx.doi.org/10.3389/fimmu.2020.539654

Ejemplares similares

Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis
por: Wang, Haiyong, et al.
Publicado: (2021)

Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC
por: Fan, Lilv, et al.
Publicado: (2021)

Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance
por: Han, Ping, et al.
Publicado: (2019)

T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
por: Li, Fanlin, et al.
Publicado: (2022)

Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors
por: Feucht, J., et al.
Publicado: (2020)

Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection
por: Zhang, Xiaoqing, et al.
Publicado: (2021)

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
por: Qi, Xinyue, et al.
Publicado: (2019)

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
por: Liang, Jie, et al.
Publicado: (2021)

Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors
por: Muliaditan, Tamara, et al.
Publicado: (2021)

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation
por: Halim, Leena, et al.
Publicado: (2022)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo
por: Li, Fanlin, et al.
Publicado: (2023)

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2019)

CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells
por: Mezősi-Csaplár, Marianna, et al.
Publicado: (2023)

Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia
por: Wu, Lijuan, et al.
Publicado: (2023)

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody
por: Chen, Ying, et al.
Publicado: (2017)

Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
por: Tang, Xiao-Yi, et al.
Publicado: (2016)

Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
por: Qin, Le, et al.
Publicado: (2017)

4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors
por: Long, Adrienne H., et al.
Publicado: (2015)

Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells
por: de Campos, Najla Santos Pacheco, et al.
Publicado: (2022)

Boosted H->bb Tagger In Run II
por: Sahinsoy, Merve
Publicado: (2016)

Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells
por: Yang, Liu, et al.
Publicado: (2021)

Mechanisms of failure of chimeric antigen receptor T-cell therapy
por: Li, Xiaoqing, et al.
Publicado: (2019)

Reconstructing low mass boosted A→bb at LHCb
por: Bokan, Petar
Publicado: (2014)

A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing
por: Prapa, Malvina, et al.
Publicado: (2015)

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
por: Yu, Jiayi, et al.
Publicado: (2018)

Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma
por: Murayama, Yudai, et al.
Publicado: (2021)

Galunisertib enhances chimeric antigen receptor-modified T cell function
por: Wang, Zhixiong, et al.
Publicado: (2020)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
por: Zhang, Erhao, et al.
Publicado: (2018)

Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
por: Zou, Yixin, et al.
Publicado: (2018)

Search for boosted ttH(H->bb) with the ATLAS detector
por: Winkels, Emma
Publicado: (2018)

First look at boosted Z → bb̄ in Run-3 data
por: Kyprianou, Afroditi
Publicado: (2023)

Research advances in chimeric antigen receptor-modified T-cell therapy (Review)
por: Luo, Yuxi, et al.
Publicado: (2021)

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
por: Ying, Zhitao, et al.
Publicado: (2021)

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition
por: Condomines, Maud, et al.
Publicado: (2015)

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018)

Efficient derivation of chimeric-antigen receptor-modified T(SCM) cells
por: Kranz, Emiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q09jheko8nd4vetmq91ut883ui